Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with i...
Journal Information
Vol. 145. Issue 3.
Pages 108-111 (August 2015)
Share
Share
Download PDF
More article options
ePub
Visits
19
Vol. 145. Issue 3.
Pages 108-111 (August 2015)
Brief report
Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect
Hipofosfatemia asociada a la administración intravenosa de hierro carboximaltosa en pacientes con anemia ferropénica. Un efecto secundario frecuente
Visits
...
Rebeca Sánchez Gonzáleza,1, Hugo Guillermo Ternavasio-de la Vegaa,1,
Corresponding author
, Leticia Moralejo Alonsob, Sandra Inés Revueltab, Aurelio Fuertes Martínb
a Servicio de Medicina Interna, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
b Unidad y Consulta de Atención Inmediata (UCAI), Servicio de Medicina Interna, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. Characteristics at baseline and in accordance with hypophosphataemia onset following administration of ferric carboxymaltose by the intravenous route in the patients enrolled in the study.
Abstract
Objectives

To determine the frequency, severity, time of onset and factors associated with the development of hypophosphatemia (HF) in patients with iron deficiency anemia treated with intravenous ferric carboxymatose (ivFCM).

Material and methods

Retrospective cohort study in patients iron deficiency anemia who received ivFCM and had an a prior and subsequent determination of serum phosphate. We carried out a comparative analysis between baseline and post-ivFCM levels of serum phosphate. In order to identify variables independently associated with HF a logistic regression analysis was also performed.

Results

One hundred twenty-five patients were included. HF frequency was 58%. The median time to onset of HF was 18days. Age, baseline ferritin levels and baseline phosphate levels were independently associated with the development of HF. The risk of HF in patients with baseline phosphate levels ≤3.1mg/dl was 67% higher than patients with ≥3.7mg/dl.

Conclusions

ivFCM-associated HF is a frequent, early and, sometimes, prolonged effect in patients with iron deficiency anemia. Serum phosphate levels should be monitored after ivFCM administration, especially in older patients and in those with lower baseline phosphate or ferritin levels.

Keywords:
Iron deficiency anemia
Ferric carboxymaltose
Hypophosphatemia
Resumen
Objetivos

Determinar la frecuencia, gravedad, momento de aparición y variables asociadas al desarrollo de hipofosfatemia (HF) en pacientes con anemia ferropénica tratados con hierro carboximaltosa por vía intravenosa (HCMiv).

Material y método

Estudio de cohortes retrospectivo en pacientes que contaran con determinaciones de fosfato previa (normal) y posterior a la administración de HCMiv. Se compara la concentración de fosfato basal y posterior a la administración de HCMiv, y mediante regresión logística binaria se determinan las variables asociadas con la HF.

Resultados

Se incluyeron 125 pacientes. La frecuencia de HF fue del 58%. El tiempo medio hasta la aparición de HF fue de 18d. La edad, las concentraciones basales de ferritina y de fosfato se relacionaron con el desarrollo de HF. El riesgo de HF de los pacientes con fosfato basal ≤3,1mg/dl fue un 67% mayor que en pacientes con fosfato basal ≥3,7mg/dl.

Conclusiones

La HF asociada a HCMiv en pacientes con anemia ferropénica es un efecto frecuente, precoz y en ocasiones prolongado. En pacientes mayores, con fosfato y ferritina más bajas, se debe vigilar el fosfato tras la administración de HCMiv.

Palabras clave:
Anemia ferropénica
Hierro carboximaltosa
Hipofosfatemia

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos